Updated:
ByHeart
ByHeart is a vertically integrated infant formula company based in New York, United States.
ByHeart
ByHeart was founded to produce whole-nutrition infant formula with a focus on clean ingredients and safety. The company built its own manufacturing facilities rather than contract out, giving it direct control over production. Wealth origin for the entity known as ByHeart is not publicly disclosed. ByHeart's strategy centers on vertical integration of formula production, including owned facilities, rigorous supplier standards, and third-party lab testing. The firm sources organic grass-fed whole milk powder and other ingredients subject to its Supplier Approval Program. Confirmed investments include ownership of its production sites and a supply chain that spans US farms and ingredient processors. The firm distributes directly to consumers via ByHeart.com and through retail partners. ByHeart's team size and organizational structure are not publicly disclosed. The company maintains a single headquarters in New York, United States, per Altss research. On February 26, 2026, the CDC and FDA declared the infant botulism outbreak ended, with no new cases since December 2025; the FDA investigation into root cause continues (per ByHeart website, February 2026). ByHeart's structural differentiator is its self-owned manufacturing in an industry typically dominated by contract manufacturers and two large players. The company's governance relationship with its capital source is opaque — no family office or asset manager is disclosed as owning or directing the firm.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Frequently asked questions
Who controls ByHeart's investment and operational decisions?
ByHeart does not publicly disclose its ownership or governance structure. No named family office, principal, or investment committee is identified on the firm's website. The company's capital source and decision-making hierarchy are not known.
Does ByHeart engage in direct investments or fund commitments beyond its own business?
ByHeart presents itself as an operating company — a manufacturer and seller of infant formula — rather than an investment vehicle. There is no public evidence that ByHeart makes external investments or fund commitments.
How is ByHeart's manufacturing structured differently from competitors?
ByHeart owns its production facilities, unlike many formula brands that contract manufacturing to third parties. This vertical integration gives ByHeart direct oversight of its supply chain and quality control, according to the firm's public statements.
What triggered the November 2025 recall of all ByHeart products?
On November 7, 2025, the FDA notified ByHeart of a potential link between its formula and cases of infant botulism. ByHeart issued a voluntary recall of two batches within 24 hours and expanded it to all products by November 11, 2025 (per ByHeart website). The company paused all production and has not resumed as of February 2026.
Has the FDA determined a root cause for the contamination?
As of February 26, 2026, the FDA's investigation is ongoing. The FDA has confirmed that whole genome sequencing matched C. botulinum Type A samples from ByHeart formula, a supplier's organic whole milk powder, and a clinical sample (per ByHeart website, February 2026). ByHeart's own testing at IEH Laboratories confirmed the presence of C. botulinum in unopened cans.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: